Sienna Biopharmaceuticals losses higher than analysts expected

You are here: Home > Central Coast Health Watch > Current Article

Sienna Biopharmaceuticals losses higher than analysts expected

By Staff Report / Thursday, August 9th, 2018 / Comments Off on Sienna Biopharmaceuticals losses higher than analysts expected

Research and development expenses more than doubled at Westlake Village-based Sienna Biopharmaceuticals during a “busy” second quarter, the company reported Aug. 9. Net losses were $1 per share, down from $6.50 per share for the previous second quarter, but still higher than analyst estimates of around 62 cents. Shares had fallen more than 3 percent…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.